RSS   Newsletter   Contact   Advertise with us

Protagonist Therapeutics appoints Sarah O'Dowd as independent director

Christian Fernsby | Newark, Ca., USA | August 14, 2020
Sarah O'DowdProtagonist Therapeutics, a clinical-stage biopharmaceutical company, announced the appointment of Sarah O'Dowd as an independent director to the Protagonist board of directors.
Ms. O'Dowd has been a director of Ichor Holdings since May 2020.

Ms. O'Dowd previously served as Senior Vice President, Chief Legal Officer and Secretary at the global technology firm Lam Research Corporation from October 2008 to March 2020.

She also served as Lam Research's Vice President of Human Resources from 2009 to 2012.

Ms. O'Dowd's experience includes the role of Vice President and General Counsel at FibroGen, a biopharmaceutical company, and a position on the board of directors of Corcept Therapeutics, a pharmaceutical company.

Ms. O'Dowd began her career at the law firm Heller Ehrman, where she held responsibility for business strategy.

She holds a J.D. from Stanford Law School, an M.A. from Stanford University, and an A.B. from Immaculata College.